Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Pharma can breathe easy over China's tort law, for now

This article was originally published in Scrip

Executive Summary

Companies operating in China are coming to grips with the potential impact of the country's first comprehensive tort liability legislation, including its provisions on product recalls and punitive damages. How worried should they be, asks Eugene Chen.

You may also be interested in...

Market Insight - Chinese lawsuits point to emerging litigious culture

In the face of robust pharmaceutical market growth, an increase in adverse drug reactions and higher consumer demands, is China's drugs industry facing a perfect storm, asks Eugene Chen.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts